Events

Avis De Sécurité sur superDimension Bronchus System

Selon Swiss Agency for Therapeutic Products, ce/cet/cette avis de sécurité concerne un dispositif en/au/aux/à Switzerland qui a été fabriqué par superDimension, Inc..

Qu'est-ce que c'est?

Les avis de sécurité sont des communications que les fabricants de dispositifs médicaux ou leurs représentants font parvenir en particulier aux travailleurs du secteur médical, mais aussi aux utilisateurs de ces dispositifs. Les avis de sécurité concernent les actions entreprises quant aux dispositifs présents sur le marché et peuvent inclure des rappels et des alertes.

En savoir plus sur les données ici
  • Type d'événement
    Field Safety Notice
  • ID de l'événement
    Vk_20120710_07
  • Date de publication de l'événement
    2012-07-30
  • Pays de l'événement
    Switzerland
  • Source de l'événement
    SATP
  • URL de la source de l'événement
    https://fsca.swissmedic.ch/mep/#?q=Vk_20120710_07
  • Notes / Alertes
    The data from Switzerland is current through March 2018. All of the data comes from Swiss Agency for Therapeutic Products, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Switzerland.
  • Notes supplémentaires dans les données

Device

superDimension Bronchus System
  • Modèle / numéro de série
    AAS00016-xx | see FSN | 4.0 - 4.9
  • Description du dispositif
    MD: Flexible video bronchoscope
  • Manufacturer
    superDimension, Inc.

Manufacturer

superDimension, Inc.
  • Société-mère du fabricant (2017)
    Medtronic plc
  • Commentaire du fabricant
    “If our surveillance systems identify a potential performance issue, our personnel promptly evaluate the problem, including, when appropriate, conducting root cause investigations and internal testing to assess whether the product continues to meet specifications and defined performance criteria,” Medtronic told ICIJ in a statement. “In some cases, based on this evaluation, Medtronic may determine that a recall is necessary.” The company said that it communicates with healthcare providers and/or patients and provide recommendations to address such issues. Medtronic noted that these communications can include letters, emails, calls, press releases, physician notifications and social media postings, as well as informing the FDA and other regulators of the actions.
  • Source
    SATP